of these patients almost only in the hands of our colleagues urologists.
The reasons for such an attitude are diverse and include the fact that many patients affected with MIBC are unsuitable-or else are perceived as such-for cisplatin (CDDP)-based combinations. 6 Such CDDP ineligibility is mainly due to the presence of concomitant illnesses in an often aging patient population: cardiovascular diseases and more often renal impairment above all. 6 Presently, CDDPineligible patients are usually treated with carboplatin (CBDCA), although it proved to be less active than the parental compound, at least in this disease. 7 Not only chronic kidney disease (CKD) is indeed quite common in patients with MIBC cancer, but it is also an important risk factor for tumor recurrence and progression toward muscle-invasive forms, as well as a predictor of poor overall survival, 8 completing a sort of perverted bidirectional relationship. Notably, a similar correlation has been demonstrated not only for bladder cancer but also for upper urinary tract urothelial carcinomas, 9 whose management is often complicated, from a nephrological viewpoint, by the consequences of nephrectomy.
As far as medical oncologist, for years those devoted to the management of urothelial cancer patients have been consequently few, and somehow frustrated, having had to deal with complex patients without an adequate therapeutic armamentarium for many of them; the recent development of several immune-checkpoint inhibitors as novel treatment strategies for urothelial cancer patients, 10 including those not suitable for CDDP, 11 is changing this situation upside-down, reinvigorating the interest of oncologists toward these cancer, not only in the metastatic setting but also in the earlier stages of the disease.
Although immune-checkpoint inhibitors, being monoclonal antibodies, are eliminated through the reticuloendothelial system and not through the kidney 12 and can thus be administered to patients with mild to moderate renal impairment-while for those with more severe impairment, as always, data are lacking-they can sometimes cause immune-mediated kidney adverse events. 13 Urothelial cancer is thus a family of neoplasms characterized by an extremely high incidence of kidney impairment throughout its whole natural history, while surgical and medical treatments-the latter including cytotoxic chemotherapy, biological agents, as well as immunecheckpoint inhibitors-often impact on kidney function, or cause renal adverse events; given this scenario, one could wonder how interesting these cancers should be for nephrologists.
Is this the case? Absolutely not.
We have recently identified 10 topics the new subspecialty of onco-nephrology should take care of; 14 according to all the above considerations, urothelial cancer should join this list as soon as possible.
The role of the nephrologist-and of an onco-nephrologist in particular-would be key to support urologists and oncologists toward a really comprehensive and multidisciplinary management of these patients.
And particularly urothelial cancer patients would greatly benefit by a more active involvement of nephrologists in their management.
First, a dedicated onco-nephrologist could help to deal with episodes of acute kidney injury (AKI) or of a worsening of CKD due to obstruction/infections, episodes which are quite common in patients with non muscle invasive bladder cancer (NMIBC) undergoing several trans-uretral resections (TURs); indeed, urinary tract infection (UTI) has been reported in as many as 7% of patients undergoing TURs, irrespective of the specific technique used. 15 I f not managed adequately, these episodes may chronicize, especially in the elderly or in diabetic patients, leading to a kidney injury which ultimately may impact the chance of receiving further active treatments when needed.
In MIBC, the nephrologist could contribute-acting both before, as well as during, therapy-to reduce the number of patients unsuitable for CDDP-based neo-adjuvant (or adjuvant) chemotherapy, or of those who cannot complete the scheduled treatment due to a deterioration in their kidney function. 16, 17 In patients receiving nephrectomy (in the case of upper urinary tract neoplasms) or cystectomy, either with neobladder or urinary diversion (in the case of bladder cancers), renal function deterioration is extremely common. Indeed, of patients with an ileal conduit, 29% have reportedly some degree of kidney impairment in the long term; 18 post-operative hydronephrosis, pyelonephritis, and uretero-enteric stricture represent other potentially modifiable factors associated with a decrease in kidney function. 19 Furthermore, other modifiable, non-surgery-related factors, which have been demonstrated to impact post-operative renal function fall into the field of expertise of nephrologists, including hypertension, pre-operative CKD with an estimated glomerular filtration rate (eGFR) of less than 50 mL/min, as well recurrent urinary infections. 18 Finally, in the metastatic setting, the nephrological management of renal toxicities from systemic therapies would be increasingly important. Beyond CDDP-still the backbone of polychemotherapy regimens-and other cytotoxics (e.g. gemcitabine and vinflunine) which may induce, directly or indirectly, renal toxicity, immunecheckpoint inhibitors have proved to induce immunemediated nephrological adverse events (both interstitial nephritis, as well as electrolytes disturbances). 13 As far as targeted agents, despite a series of failure in the past decade, recently the anti-vascular endothelial growth factor receptor (VEGFR)-2 monoclonal antibody ramucirumab proved to be active in the metastatic setting, 20 heading for a global registration; thus, the management of renal adverse events related to the inhibition of the vascular endothelial growth factor (VEGF)/VEGFRs pathway will fall within the competences of nephrologists also in these tumors. 21 As a whole, these are the reasons-in our opinionnephrologists should be involved in the management of patients with urothelial cancers, being an active player within a dedicated multidisciplinary team.
